Recent Updates
Recently added Catalysts

Cariprazine Flexible Dose

Phase 3

Schizophrenia | Small molecule | Psychiatry |AbbVie Inc.|Last Updated: Oct 27, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment310
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04578756Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderPHASE3 COMPLETED 310Feb 1, 2021Oct 6, 2025Oct 27, 202542 United States, Puerto Rico
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period
Baseline Day 1 to Week 59

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.

Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Baseline Day 1 to Week 52

Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.

Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
Baseline Day 1 to Week 59

Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.

Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
Baseline Day 1 to Week 52

A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.

Number of Participants With Suicidal Ideation or Suicidal Behavior as Recorded on the Columbia-Suicide Severity Rating (C-SSRS) Scale
Baseline Day 1 to Week 52

C-SSRS is a clinician-rated scale that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 "wish to be dead," and 5 "active suicidal ideation with specific plan and intent". Suicidal behavior is classified on a 5-item scale: 0 "no suicidal behavior, and 4 "actual attempt".

Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Baseline Day 1 to Week 52

AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.

Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Baseline Day 1 to Week 52

BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \[0\] to severe \[3\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \[0\] to severe akathisia \[5\]).

Change From Baseline in Simpson-Angus Scale (SAS)
Baseline Day 1 to Week 52

SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.

Number of Participants With Clinically Significant Changes From Baseline in Opthalmologic Parameters
Baseline Day 1 to Week 52

Ocular examination parameters included Intraocular pressure (IOP) measurement, Best-corrected visual acuity (BCVA), color fundus photography, color vision testing using Hardy Rand and Rittler (HRR) plates, and assessment of Optical coherence tomography (OCT) and cataracts. The investigator assessed the results for clinical significance.

Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cariprazine Dose 1EXPERIMENTALParticipants with Schizophrenia (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine.
Cariprazine Dose 2EXPERIMENTALParticipants with Schizophrenia (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
Cariprazine Dose 3EXPERIMENTALParticipants with Bipolar I Disorder (age 10 to 12 years and \<40 kg body weight) will receive cariprazine.
Cariprazine Dose 4EXPERIMENTALParticipants with Bipolar I Disorder (age 10 to 12 years and \>= 40 kg body weight) will receive cariprazine.
Cariprazine Dose 5EXPERIMENTALParticipants with Bipolar I Disorder (age 13 to 17 years and \< 40 kg body weight) will receive cariprazine.
Cariprazine Dose 6EXPERIMENTALParticipants with Bipolar I Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
Cariprazine Dose 7EXPERIMENTALParticipants with Autism Spectrum Disorder ( age 5 to 9 years) will receive cariprazine.
Cariprazine Dose 8EXPERIMENTALParticipants with Autism Spectrum Disorder (age 10 to 12 years and \<40 kg weight) will receive cariprazine.
Cariprazine Dose 9EXPERIMENTALParticipants with Autism Spectrum Disorder (age 10 to 12 years and \>=40 kg body weight) will receive cariprazine.
Cariprazine Dose 10EXPERIMENTALParticipants with Autism Spectrum Disorder (age 13 to 17 years and \<40 kg weight) will receive cariprazine.
Cariprazine Dose 11EXPERIMENTALParticipants with Autism Spectrum Disorder (age 13 to 17 years and \>= 40 kg body weight) will receive cariprazine.
Interventions
NameTypeDescription
Cariprazine Flexible DoseDRUG1 capsule to be taken orally at approximately the same time of day (morning or evening)
Unlock Study Design Details
Eligibility Criteria
Age Range5 Years — 17 Years
SexALL
Healthy VolunteersNo
Study Sites42

Inclusion Criteria: * Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of schizophrenia or bipolar I disorder, or autism spectrum disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for S...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria